Statement of Organization, Functions, and Delegations of Authority

---
identifier: "/us/fr/2022-26280"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Statement of Organization, Functions, and Delegations of Authority"
title_number: 0
title_name: "Federal Register"
section_number: "2022-26280"
section_name: "Statement of Organization, Functions, and Delegations of Authority"
positive_law: false
currency: "2022-12-02"
last_updated: "2022-12-02"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2022-26280"
document_type: "notice"
publication_date: "2022-12-02"
agencies:
  - "Health and Human Services Department"
  - "National Institutes of Health"
  - "Food and Drug Administration"
fr_citation: "87 FR 74154"
fr_volume: 87
fr_action: "Notice."
---


#  Statement of Organization, Functions, and Delegations of Authority

**AGENCY:**

National Institutes of Health and Food and Drug Administration, HHS.

**ACTION:**

Notice.

**SUMMARY:**

The Secretary of Health and Human Services delegates to the National Institutes of Health (NIH) Director and the Food and Drug Administration (FDA) Commissioner the authorities vested in the Secretary of Health and Human Services under Section 3 of the Accelerating Access to Critical Therapies for ALS Act, as amended, to establish and implement a Public-Private Partnership for rare neurodegenerative diseases. These authorities may be redelegated. Exercise of this authority shall be in accordance with established policies, procedures, guidelines, and regulations as prescribed by the Secretary. The Secretary retains the authority to submit reports to Congress and promulgate regulations.

**DATES:**

This authority delegation was approved by the Secretary of Health and Human Services on November, 29, 2022.

Dated: November 29, 2022.

Xavier Becerra,

Secretary, Department of Health and Human Services.